Microdosing Mescaline for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Microdosing Mescaline for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Mescaline is a psychedelic compound found in several cacti; microdosing means taking amounts below the level that changes perception, repeated over weeks, for steadier mood and easier focus. Not one controlled study has tested mescaline at microdose amounts in people, and none is registered. Reported gains may be expectation. Costs are concrete: nausea, raised blood pressure, disturbed sleep, weaker concentration, and serious criminal exposure in most countries. (Full Review)

Protocol

Starting dose
10–15 mg
Mescaline hydrochloride, about one-twentieth of a 300 mg full dose; held at least three dosing occasions before increments of no more than 5 mg; weighed on a 1 mg balance.
Schedule
1 day on, 2 days off
Most widely used, though none is presented as a default; the 48-hour minimum, never daily, is the point of agreement. Single dose. Blocks of 4–8 weeks.
Best time of day
Morning, before 10:00
Administered orally with a small quantity of food to reduce nausea. Afternoon dosing risks sleep-onset delay.
Time to effect
Acute effects
1–2 hours
Onset at roughly 1 hour, peak at 2 hours after an oral dose.
Effect duration
3–6 hours
3.5-hour half-life; over 95% eliminated within 18 hours.
Claimed cumulative benefit
2–4 weeks
Blinded trials at this horizon found no separation from placebo.

Benefits

Contraindications
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, moclobemide, linezolid, harmala alkaloids in Peganum harmala)
  • Lithium
  • Personal or first-degree-relative schizophrenia, schizoaffective or bipolar I disorder
  • Uncontrolled hypertension (seated systolic ≥ 160 or diastolic ≥ 100 mmHg)
  • Coronary artery disease; myocardial infarction within 90 days
  • Moderate or severe valvular heart disease
  • Heart failure, New York Heart Association Class III or IV
  • Chronic kidney disease (eGFR below 45 mL/min/1.73 m²)
  • Severe hepatic impairment (Child-Pugh Class C)
  • Epilepsy or any seizure disorder
  • Pregnancy, attempted conception, breastfeeding
  • Safety-critical duties, commercial driving or flight, workplace drug screening
    •
Key Interactions
  • Selective serotonin and serotonin-noradrenaline reuptake inhibitors (fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine)
  • Tricyclic antidepressants (amitriptyline, imipramine, clomipramine)
  • Antipsychotics and other serotonin 2A blockers (risperidone, olanzapine, quetiapine, trazodone, mirtazapine)
  • Serotonergic and stimulant medications (sumatriptan, tramadol, amphetamine salts, methylphenidate)
  • Antihypertensives (metoprolol, lisinopril, amlodipine)
  • Over-the-counter medications (dextromethorphan, pseudoephedrine, phenylephrine, diphenhydramine)
  • Serotonergic supplements (5-hydroxytryptophan, L-Tryptophan, S-adenosylmethionine, St. John's wort)
  • Cardiovascular-stimulant supplements (caffeine, yohimbine, synephrine, green tea extract)
  • Heat exposure (sauna, hot yoga), extended fasting, alcohol, prolonged high-intensity exercise

Risk & Side Effects

  • High: Nausea and vomiting; blood pressure and heart rate elevation; criminal legal exposure; product misidentification and adulterant substitution
  • Medium: Anxiety, restlessness and irritability; impaired cognitive control; sleep disruption; headache
  • Low: Serotonin 2B receptor–mediated cardiac valve injury; persisting perceptual disturbance and "flashbacks"; precipitation of psychosis or mania in predisposed individuals
  • Speculative: Cumulative cardiovascular strain from chronic repeated dosing; long-term serotonin 2A receptor downregulation

Monitoring

Marker Target Why
Seated blood pressure 105–120 / 65–78 mmHg Detects the documented blood-pressure rise; sets the safety margin
Resting heart rate 50–65 beats per minute Baseline for the heart-rate effect; rising trend signals load
12-lead electrocardiogram with QTc interval QTc < 440 ms (men), < 450 ms (women) Screens for conduction abnormality that would amplify the effect
Creatinine and estimated glomerular filtration rate eGFR > 90 mL/min/1.73 m² Roughly half of a dose is cleared renally, so filtration sets exposure
Alanine and aspartate aminotransferase ALT 10–26 U/L, AST 10–26 U/L Flags hepatic stress; supervised full-dose studies found no change
Complete blood count Within reference, ferritin 50–150 ng/mL Supervised studies found no change, so any change points elsewhere
High-sensitivity C-reactive protein < 0.5 mg/L Tracks the proposed anti-inflammatory benefit, entirely speculative
Glycated haemoglobin 4.8–5.3% Metabolic context; serotonergic agents can alter appetite
Thyroid-stimulating hormone with free thyroxine TSH 0.5–2.0 mIU/L Untreated thyroid dysfunction mimics the benefits and the anxiety effect
Transthoracic echocardiogram No valvular regurgitation beyond trivial Screens the theoretical serotonin 2B valvular pathway; only beyond a year of frequent dosing

Cadence: Blood pressure and heart rate before and 2 hours after the first four doses, then weekly for the rest of a block; laboratory panel at 3 months, then every 6–12 months; echocardiography only beyond 12 months of frequent dosing.

Qualitative Assessment

  • Sleep onset latency and total sleep time, ideally from a wearable
  • Morning anxiety and physical restlessness
  • Sustained attention and ability to suppress distraction
  • Irritability and emotional reactivity, particularly the day after a dose
  • Social engagement and warmth toward others
  • Perceptual anomaly — trails, halos, static — persisting into a non-dosing day; a stop signal
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.